linjc16/ctgov huggingface dataset:
Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)

Study Overview
=================
Brief Summary
-----------------
This study aim to calculate the minimal effective ropivacaine concentration required achieve successful analgesic interscalene block in 90% of patients (MEAC90)

Detailed Description
-----------------
Before induction of general anesthesia, all patients will receive interscalene block using 15ml of ropivacaine which concentration will be based on the response of the previous patient. Based on biased-coin design up-down sequential method: if patient has pain free recovery, a successful block, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less. However, if he has an unsuccessful block, the next patient will receive a concentration 0.01% w/v higher. Patients with pain free recovery will be considered to have positive response. Patients' responses will be analyzed to calculate the MEAC90.

Official Title
-----------------
Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Ropivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, who are scheduled for shoulder arthroscopy Exclusion Criteria: - <18 y, ASA physical class greater >III BMI >40 has any contraindication for medications or techniques used in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ropivacaine|all patients will receive interscalene block using same volume of ropivacaine but in different concentrations|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effective analgesic interscalene block | postoperative pain (will be assessed using numerical rating scale. if ≥ 3, ineffective block will be considered and if <3, an effective block will be considered | in recovery unit (one hour after surgery) |
Problematic Use of the Internet in Child and Adolescent Psychiatry

Study Overview
=================
Brief Summary
-----------------
Pathological internet use is a blanket term for problematic behavior types (e.g. uncontrolled gaming, cyber pornography, cyber mobbing and excessive use of social media): all perpetrated through the internet. There is little documentation or research on interdependencies/interplay between problematic internet and/or media use and child-adolescent disturbances. Very few clinical examples of syndromes like attention deficiency/hyperactivity (ADHS), anxiety disorder or affective disturbances associated with pathological media/internet use, or gaming, are found in literature.

Official Title
-----------------
Problematic Use of the Internet in Child and Adolescent Psychiatry

Conditions
-----------------
Substance Use Disorders

Intervention / Treatment
-----------------
* Diagnostic Test: screening questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and female patients ages from 8 - 18 years All study participants or their legal representative have given written permission for their experiences to be documented in the study. Exclusion Criteria: Inability to understand explanations and the questionnaire, whether linguistic or cognitative

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients<br>male and female patients, handled on an ambulatory basis in Psychiatric University Clinics, Department of Child and Adolescent Psychiatrythe ages from 8 - 18 years during the study | Diagnostic Test: screening questionnaire<br>* Fill in screening questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms severity of problematic internet and media use | The clinician screening questionnaire (PUI) contains 9 items designed to assess severity of problematic internet and media use of obsessive and compulsive in children and adolescents.The test uses a 4-point scale to rate severity of problematic internet and media use. Higher score means a worse outcome. | 3 months |
Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only

Study Overview
=================
Brief Summary
-----------------
This is a Phase III trial comparing hepatic intra-arterial injection of Yttrium-90 microspheres (selective internal radiation [SIR] spheres) versus infusional intravenous (IV) 5FU in colorectal cancer metastatic to the liver only and refractory to standard IV chemotherapy.

Official Title
-----------------
Comparison Hepatic Intra-arterial Injection of Yttrium-90 Versus 5FU in Colorectal Cancer Metastatic to the Liver Only

Conditions
-----------------
Colorectal Neoplasm, Secondary Malignant Neoplasm of Liver

Intervention / Treatment
-----------------
* Device: SIR Spheres intra-arterial hepatic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven colorectal adenocarcinoma, metastatic to the liver only. Failure of prior chemotherapy for advanced colorectal cancer. Adequate laboratory values of hematologic, renal and liver function World Health Organization (WHO) performance status (PS) <= 2 Written consent Exclusion Criteria: Pregnant or lactating patients Other tumor type than adenocarcinoma (leiomyosarcoma; lymphoma). Patients with cirrhosis or other chronic liver disease Thrombosis of the hepatic main artery of the portal vein Lung shunting > 20% as determined by nuclear medicine breakthrough scan Patients with serum bilirubin > 1.0 x upper limit of normal (ULN) or with AST and/or ALT and/or alkaline phosphatase > 5 x ULN Patients with concurrent or within 4 week period administration of any other experimental drugs. Other serious illness or medical conditions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: SIR Spheres intra-arterial hepatic|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal cancer, liver metastasis, intraarterial hepatic injection, yttrium loaded microspheres, colorectal neoplasm metastatic to the liver
Changes in Cerebral Oxygenation During Deliberate Hypotensive Anesthesia

Study Overview
=================
Brief Summary
-----------------
This is a study using cerebral oximetry to evaluate the safety of traditionally adopted hypotensive anesthesia.

Detailed Description
-----------------
The values of cerebral oximetry were analyzed between different stages of anesthetic management. The critical part of anesthetic management is to use the technique of controlled hypotension. The blood pressure was lowered to the level of MABP 50 or 60 mmHg depending on which group patients were assigned to. The values of cerebral oximetry and side effects between 2 groups will be compared at the completion of data collection.

Conditions
-----------------
Hypotension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40 patients are going to receive complex spine surgery. Exclusion Criteria: Neurologic diseases Hepatic or renal impairment Uncontrolled hypertension Cardiovascular diseases

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
controlled hypotension
Surgeon-Anesthesiologist Collaboration

Study Overview
=================
Brief Summary
-----------------
Collaboration between the surgeon and the anesthesiologist is key for delivering a safe pheochromocytoma surgery. This study aims to establish the collective performance of surgeon-anesthesiologist team by quantifying the relationship between their previous collaborations and patient complications.

Official Title
-----------------
Influence of Surgeon-anesthesiologist Collaboration on Patient Outcomes After Pheochromocytoma Surgery

Conditions
-----------------
Pheochromocytoma, Collaboration

Intervention / Treatment
-----------------
* Procedure: Surgery complications


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who underwent surgical procedure for pheochromocytoma in 8 French university hospitals from January 2000 to December 2016 Exclusion Criteria: Age < 18 years old Patients operated for incidentaloma or with paraganglioma diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pheochromocytoma<br>Patient who underwent surgical procedure for pheochromocytoma | Procedure: Surgery complications<br>* Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of an intraoperative hemodynamic instability | An intraoperative hemodynamic instability is defined as the occurrence of at least one intraoperative episode of systolic blood pressure ≥ 160 mmHg and at least one episode of mean blood pressure ≤ 60 mmHg | At the time of surgery (less than 4 hours) |
Emotional Brain Processes in Recreational Cannabis Users

Study Overview
=================
Brief Summary
-----------------
This fMRI study investigates neural correlates of emotion regulation, emotion processing and craving in recreational cannabis users.

Official Title
-----------------
Effects of Recreational Cannabis Use on Brain Activation Patterns Associated With Emotional Processes

Conditions
-----------------
Recreational Cannabis Use

Intervention / Treatment
-----------------
* Other: fMRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recreational cannabis use 72 hours of abstinence Exclusion Criteria: neurological disorders psychiatric disorders according to DSM-4

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Recreational Cannabis Use<br>ages 18-40 | Other: fMRI<br> <br> |
| Healthy control subjects<br>socio-demographically matched | Other: fMRI<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fMRI neural correlates of emotional brain processes in recreational cannabis users after 72 hours of abstinence | Activation patterns in brain regions known to be involved in emotional processing and to be altered by cannabis use (e.g. striatum, prefrontal cortex, insula, ACC) | one time point = fMRI assessment after 72 hours of abstinence | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ratings of subjective experience (affect, craving) |  | one time point = during fMRI assessment after 72 hours of abstinence | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cannabis, fMRI, emotion
JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
The Purpose of this trial is: to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Official Title
-----------------
A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Conditions
-----------------
Recurrent Classical Hodgkin Lymphoma

Intervention / Treatment
-----------------
* Drug: Ruxolitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: relapsed or refractory HL ECOG <= 2, no major organ dysfunction written informed consent Exclusion Criteria: history of another primary malignancy ≤ 2 years female patients who are pregnant or breast feeding patients with a known history of HIV seropositivity chronic active hepatitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ruxolitinib<br> | Drug: Ruxolitinib<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall response rate |  | 8 weeks |
Monitoring of Overdose Patients With and Without Supplemental Oxygen in the Emergency Department

Study Overview
=================
Brief Summary
-----------------
This study will compare the data from pulse oximeters to capnographers as they are used to monitor patients who are being observed in the Emergency Department for a suspected overdose of alcohol or other drugs. The investigators will compare monitor data from patients who are and are not on supplemental oxygen, the ability of the monitors to predict the occurrence of airway interventions, and to detect ventilator changes noted on the opposing monitor. There will not be any interventions during this study other than the collection of data from the monitors and observation of the care of patients.

Official Title
-----------------
Monitoring of Overdose Patients With and Without Supplemental Oxygen in the Emergency Department

Conditions
-----------------
Overdose

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Airway is being monitored as a result of overdose Exclusion Criteria: Under 18 years old Unable to give informed consent at baseline Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Overdose<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Airway Interventions Performed by ED Staff | Addition or increase in supplemental oxygen, stimulation to induce respiration, airway repositioning, bag-valve-mask application, positive pressure ventilation, intubation, airway suctioning, vomiting, medication administration, transfer to a higher level of care. | 4 hours | 
| Pulse oximetry | recorded every 5 minutes and at the time of clinical interventions | 4 hours | 
| End tidal CO2 | recorded every 5 minutes and at the time of any clinical intervention | 4 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Capnography, Overdose, Emergency Department, Supplemental Oxygen, Pulse Oximeter
Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease

Study Overview
=================
Brief Summary
-----------------
Clinicians know little about Creutzfeldt Jakob disease, and they are not proficient in the diagnostic criteria of Creutzfeldt Jakob disease, so it is easy to misdiagnose or delay the diagnosis. As a rare central nervous system disease, it is necessary, feasible and practical to evaluate the diagnostic criteria of Creutzfeldt Jakob disease.

Detailed Description
-----------------
To master the clinical application of the diagnosis of Creutzfeldt Jakob disease (WS / T 562-2017) and the problems in the implementation process; The rationality, practicability and operability of the diagnostic criteria were evaluated scientifically; Reduce the misdiagnosis rate; To provide clinical basis and suggestions for further improving the diagnostic criteria. Through consulting the literature of Creutzfeldt Jakob disease, the clinical manifestations, laboratory examination, auxiliary examination and pathological results of Creutzfeldt Jakob disease were analyzed and compared with the current diagnostic criteria; The clinical diagnosis and misdiagnosis of Creutzfeldt Jakob disease were analyzed; To train medical staff at all levels to apply the diagnostic criteria of Creutzfeldt Jakob disease, and to discuss the clinical cases of Creutzfeldt Jakob disease in many hospitals.

Official Title
-----------------
Follow up Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease (WS / T 562-2017)

Conditions
-----------------
Creutzfeldt Jakob Disease

Intervention / Treatment
-----------------
* Diagnostic Test: laboratory examination, auxiliary examination, pathological results


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Creutzfeldt Jakob disease Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Creutzfeldt Jakob disease<br>Patients with Creutzfeldt Jakob disease | Diagnostic Test: laboratory examination, auxiliary examination, pathological results<br>* Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical manifestations | Clinical manifestations of patients | 1 year |
Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
To evaluate the clinical outcomes of the systemic re-esterified triglyceride (rTG) form of omega-3 fatty acids in patients with dry eye symptoms after cataract surgery

Official Title
-----------------
Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Drug: Omega 3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non complicated cataract surgery Patients with dry eye symptom Exclusion Criteria: Using steroid eyedops, Using antibiotics eyedrops Surgery other than Cataract surgery Contact lens wearer Other systemic disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Omega<br>Omega-3 re-esterified triglyceride form | Drug: Omega 3<br>* rTG form Omega-3<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dry eye symptom | Improvement of symptom | 1 month |